TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 62.5% in September

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 51,200 shares, an increase of 62.5% from the September 15th total of 31,500 shares. Approximately 1.0% of the company's shares are short sold. Based on an average daily volume of 46,000 shares, the days-to-cover ratio is currently 1.1 days.

Insider Activity

In other news, CEO Mary T. Szela purchased 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the transaction, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 76.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of TLSI. Wolverine Asset Management LLC purchased a new position in TriSalus Life Sciences in the 2nd quarter valued at approximately $240,000. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences in the second quarter valued at $1,184,000. Finally, Duquesne Family Office LLC raised its stake in shares of TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after purchasing an additional 110,966 shares during the period. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Stock Performance

TLSI stock remained flat at $4.24 during trading on Friday. The company had a trading volume of 34,857 shares, compared to its average volume of 40,147. The business's fifty day simple moving average is $5.01 and its 200 day simple moving average is $6.75. The firm has a market capitalization of $115.15 million, a price-to-earnings ratio of -1.70 and a beta of 0.47. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $7.36 million during the quarter. As a group, sell-side analysts predict that TriSalus Life Sciences will post -1.53 EPS for the current year.

Analysts Set New Price Targets

TLSI has been the subject of a number of recent analyst reports. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They issued an "outperform" rating and a $10.00 price target for the company. Canaccord Genuity Group restated a "buy" rating and set a $12.00 target price on shares of TriSalus Life Sciences in a research note on Thursday, June 27th.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.